Stay updated on Tipifarnib in HRAS-Mutant Squamous Head and Neck Cancer Clinical Trial
Sign up to get notified when there's something new on the Tipifarnib in HRAS-Mutant Squamous Head and Neck Cancer Clinical Trial page.

Latest updates to the Tipifarnib in HRAS-Mutant Squamous Head and Neck Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe webpage has undergone significant content changes, including the removal of detailed information about a Phase II study of tipifarnib for HRAS mutant tumors and the addition of a new version number, v2.15.0.SummaryDifference18%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check88 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
Stay in the know with updates to Tipifarnib in HRAS-Mutant Squamous Head and Neck Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tipifarnib in HRAS-Mutant Squamous Head and Neck Cancer Clinical Trial page.